Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

$111.71 -3.74 (-3.24%)

(As of 11/15/2024 ET)

Ligand Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 6 Analyst Ratings

Sell
0

Hold
0

Buy
6

Based on 6 Wall Street analysts who have issued ratings for Ligand Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for LGND.

Consensus Price Target

$144.83
29.65% Upside

According to the 6 analysts' twelve-month price targets for Ligand Pharmaceuticals, the average price target is $144.83. The highest price target for LGND is $157.00, while the lowest price target for LGND is $135.00. The average price target represents a forecasted upside of 29.65% from the current price of $111.71.

LGND Analyst Ratings Over Time

Type	Current Forecast 11/17/23 to 11/16/24	1 Month Ago 10/18/23 to 10/17/24	3 Months Ago 8/19/23 to 8/18/24	1 Year Ago 11/17/22 to 11/17/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$144.83	$131.80	$131.00	$109.75
Forecasted Upside	29.65% Upside	24.47% Upside	28.17% Upside	89.81% Upside
Consensus Rating	Buy	Buy	Buy	Buy

5 Stocks that could triple in a week (Ad)

Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.

Click here to pay just $5 for a full year of Stealth Trades

LGND Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LGND Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ligand Pharmaceuticals Stock vs. The Competition

Type	Ligand Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	29.65% Upside	28,534.31% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent LGND News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/12/2024	Royal Bank of Canada 4 of 5 stars	D. Miehm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$130.00 ➝ $140.00	+13.39%
11/8/2024	Benchmark 2 of 5 stars		Boost Target	Buy ➝ Buy	$110.00 ➝ $135.00	+12.33%
11/8/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$125.00 ➝ $150.00	+24.95%
11/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$135.00 ➝ $147.00	+22.78%
11/8/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$157.00 ➝ $157.00	+20.86%
7/9/2024	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Hewitt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$135.00 ➝ $140.00	+53.56%
My Top Trump Rally Stocks (Ad) This Catalyst Hits Once Every 4 Years.. Every four years, on the day of the election, a catalyst is triggered. Over the last 20 years, this catalyst has caused 1,500 stocks to rise an average of 3,700%... within 90 days. And now, Tim Bohen is blowing the whole story wide open on Wednesday, November 20th at 8PM. Click here for details on your FREE RSVP.
12/23/2022	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Henry Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$85.00 ➝ $90.00	+34.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:19 AM ET.

LGND Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Ligand Pharmaceuticals is $144.83, with a high forecast of $157.00 and a low forecast of $135.00.
: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares.
: According to analysts, Ligand Pharmaceuticals's stock has a predicted upside of 29.65% based on their 12-month stock forecasts.
: Ligand Pharmaceuticals has been rated by research analysts at Barclays, Benchmark, HC Wainwright, Oppenheimer, and Royal Bank of Canada in the past 90 days.
: Analysts like Ligand Pharmaceuticals more than other "medical" companies. The consensus rating for Ligand Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LGND compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

This page (NASDAQ:LGND) was last updated on 11/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target